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a  b  s  t  r  a  c  t
Human  life  expectancy  has increased  dramatically  in  the last  century  and  as a  result  also  the  prevalence
of a variety  of age-related  diseases  and  syndromes.  One  such  syndrome  is  frailty, which  is deﬁned  as
a  combination  of  organ  dysfunctions  leading  to increased  vulnerability  to  adverse  health  outcomes.  In
humans,  frailty  is associated  with  various  biomarkers  of ageing  and  predicts  relevant  outcomes  such
as  responses  to therapies  and  progression  of  health  status  and  mortality.  Moreover,  it is relatively  easy
to assess.  To  foster  translation  of mechanistic  understanding  of  the  ageing  process  and,  importantly,  of
interventions  that may  extend  healthy  lifespan,  frailty  scales  have  been  reverse  translated  into  mice  in
recent  years.  We  will  review  these  approaches  with  a view  to  identify  what  is  known  and  what  is not
known  at  present  about  their  validity,  reproducibility  and  reliability  with  a  focus  on  the potential  for
further  improvement.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Comparison of human frailty assessment tools proposed by Fried and Rockwood.
Fried’s frailty Phenotypea Rockwood’s Frailty Indexb
Clinical Syndrome Deﬁcit Accumulation
5  Phenotypic criteria Comprehensive Geriatric assessment
(up to 70 parameters)
Associated with physical features Associated with biological markers
Predictive for healthspan Frailty is not differentiated from
disability and co-morbidity
No cognitive parameter assessment Includes cognitive assessments
Low inter-rater reproducibility High inter-rater reproducibilityReferences  . . .  . . .  . .  . . . . .  . . . . . . .  . . .  . . .  .  . . .  .  . . .  . . . . . . . . . . . . . . .  . . .  . .  . .  .  . . .
. Frailty in humans: deﬁnitions and operationalisations
Over the last 170 years, human life expectancy has been con-
tantly increasing by 2–3 months every year without any indication
f a slow-down (WHO, global health and aging, 2015). Historically,
here have been different reasons for this increase, but presently,
he main cause is probably improved management of chronic, age-
ssociated diseases and disabilities. In other words, more and more
eople live longer but they suffer from an increasing number of
hronic conditions, often resulting in decreased capability to per-
orm their daily activities and they are frail.
.1. Lifespan, healthspan and longevity trap
The medium life expectancy (lifespan for short) in EU member
tates for a 50 year old person increased by 1.2 years for men  and
.1 years for women between 2005 and 2010 (Fouweather et al.,
015) while healthy life expectancy, also called “healthspan” (Van
orman, 1995) increased only by 0.5 and 0.4 years, respectively,
ver the same time frame. Healthspan is deﬁned as the length of
ime in one’s life where one is in optimal health (Van Norman,
995) and inequalities between countries are presently much larger
about 3–4 fold) compared to lifespan. In a signiﬁcant number
f European countries, healthspan did in fact decrease between
005 and 2010 (Global Health and Aging, 2015; Anon, 2016). In
he UK, 85 year olds suffer from 5 (women) or 4 (men) chronic
iseases on average at the same time (Collerton et al., 2009). The
ame trends exist worldwide, both in developed and low-income
ountries. Thus, a ‘longevity trap’ is becoming evident, inﬂicted by
ontinuously increasing life expectancy together with stagnating
ealthy and disability-free periods. It has long been recognized that
his situation urgently requires practicable and efﬁcient counterac-
ion that efﬁciently slows down the inevitable yet adaptable ageing
rocess, thereby postponing the onset of age-related disease and
isability.
.2. Frailty as clinical syndrome of accelerated ageing
The concept of frailty has been developed to describe the condi-
ions of aged people as physically weak with increased vulnerability
o adverse health outcomes (Howlett, 2015) and is considered
o be associated with a major loss of capacity to maintain tissue
omeostasis and regeneration. Since frailty affects various param-
ters required for healthy living it negatively impacts healthspan.
t is characterized by a state of age-related biological vulnerability
o stressors and decreased physiological reserves with alterations
n energy metabolism, decreased skeletal muscle mass and qual-
ty, and altered hormonal and inﬂammatory functions [reviewed
y Mohler et al., 2014]. Recent consensus deﬁned frailty as “a
edical syndrome with multiple causes and contributors that is
haracterized by diminished strength and endurance, and reduced
hysiologic function that increase an individual’s vulnerability for
eveloping increased dependency and/or death” (Morley et al.,
013). Importantly, the deﬁnition of frailty as a clinical syndrome
ather than just an intuitive description of the ‘biologically oldest’
hich speciﬁes this state as a possible endpoint for interventions
imed at expanding healthspan. It is important to stat that frailty
s a plastic condition that can deteriorate but also revert over time.
owever, full-blown frailty marks a precipitous decline in overalla Ref. Fried et al., 2001.
b Ref. Rockwood et al., 2005.
health with decreasing likelihood of recovery (Fried et al., 2001;
Walston et al., 2006).
1.3. Frailty scales: Fried’s frailty phenotype and Rockwood index
A number of frailty scales have been developed to operationalise
this concept [reviewed by Mohler et al., 2014 and Seldeen et al.,
2015]. While all scales are able to predict mortality, sensitivity and
speciﬁcity regarding the classiﬁcation of individuals as frail/non-
frail are at least partly different between the scoring systems (Theou
et al., 2013; Ravindrarajah et al., 2013; Collerton et al., 2012). The
two major frailty models that have been more extensively validated
in the literature are the “Fried frailty phenotype” and the “Rock-
wood frailty index”. Fried’s frailty phenotype deﬁnes frailty as a
distinct clinical syndrome meeting three or more of ﬁve phenotypic
criteria: weakness, slowness, low level of physical activity, self-
reported exhaustion, and unintentional weight loss (Fried et al.,
2001). In contrast, Rockwood frailty index deﬁned frailty origi-
nally as cumulative deﬁcits identiﬁed in a comprehensive geriatric
assessment (Rockwood et al., 2005). Deﬁciencies concerning more
than 70 parameters relevant to everyday activities, also comprising
physiological problems, mental capabilities, concomitant features
of co-morbidities etc. have been included in the construction of
the Rockwood frailty index. Major differences between the Fried
and Rockwood scales are shown in Table 1. Even though multi-
deﬁciency and multi-morbidity are an essential part of the frailty
index, speciﬁc number and types of deﬁciencies diagnosed have
only a minor impact on the categorization of frailty (Song et al.,
2010). Moreover, frailty scales are closely associated with a wide
range of markers of biological age, especially pro-inﬂammatory
cytokine levels (Walston et al., 2006; Collerton et al., 2012; Leng
et al., 2007). In fact, it is possible to use the same deﬁcit concept
to construct a frailty index based on biological markers of ageing
(Mitnitski et al., 2015), supporting the view of frailty as exaggerated
ageing.
2. Frailty measures in mice
There is a wide consensus in the ageing biology ﬁeld that the
time has come to apply the current understanding of the ageing
process for distinct interventions in order to improve healthspan
in humans. Mice are the most commonly used mammalian models
in ageing research because of their relative ease of genetic manipu-
lation, low cost and short lifespan (1–3 years depending on strain)
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tudies have shown similarities in ageing processes between mice
nd humans (Graber et al., 2013; Parks et al., 2012; Whitehead et al.,
014; Barreto et al., 2010) even though there are also signiﬁcant dif-
erences to humans which limits speciﬁc applications. Important
mong these are the facts that mice exhibit higher regenerative
apacities, muscle mass only minimally declines as mice age, mice
ave high telomerase activity in many organs, and mice are able to
ynthesize vitamin C (Vanhooren and Libert, 2013). Moreover, age-
elated disease spectra are very different in mice and humans, with
ancer being prevalent in mice and major neurologic decline, car-
iovascular disease and type 2 diabetes among others being muss
ess prevalent in old mice than humans. Finally, laboratory mice
re typically maintained as inbred strains, which is incomparable
o humans and complicates or might even exclude comparative
tudies of genome-environment interactions. On the other hand,
ouse breeding technology allows researchers to reduce biolog-
cal variation as a source of experimental noise and also allows
he exploitation of strain and cohort differences as a tool in ageing
esearch (see for instance (Miwa et al., 2014)). Large scale longi-
udinal and cross-sectional studies assessing not only lifespan but
lso neuromuscular, kidney and heart function, hematology, hor-
one levels, immunological parameters, body composition, bone
ensity, necropsy, pathology and apoptosis (Sundberg et al., 2011)
re available for a wide range of inbred mouse strains in the Mouse
henome Database (http://phenome.jax.org).
However, in many ageing studies, the focus has been on exten-
ion of lifespan in model organisms as a simple single criterion
or efﬁciency of an intervention to delay ageing. To develop and
alidate interventions with potential to improve healthspan in
umans with much higher impact for patients, this focus is no
onger sufﬁcient. Two overlapping approaches have been taken,
amely i) the development of measures of healthspan in mice and
i) the reverse translation of the frailty concept. The state-of-the-
rt with regard to healthspan indices in mice has very recently
een critically and exhaustively summarized by Richardson and
olleagues (Richardson et al., 2016). They recommend the assess-
ent of overall health in several domains based on the acceptance
f the full complexity of so-called ‘anti-ageing’ interventions which
ill typically be segmental, i.e. delay degeneration or even improve
ealth in some domains but result in worse outcomes in others. To
tandardize methodology, Richardson et al., 2016 compiled a com-
rehensive list of healthspan assays, providing an excellent tool for
uture intervention studies. In the present review, we will focus
n attempts to reverse translate the frailty concept into mice. In
ecent years, both the Fried frailty phenotype and the Rockwood
railty index have been translated into mice (see Table 1). These
fforts have been reviewed by (Howlett, 2015; Seldeen et al., 2015)
ut we feel that the importance of the topic warrants an update.
.1. Fried-based mouse frailty phenotype
Graber and colleagues (Graber et al., 2013) proposed a neuro-
uscular healthspan scoring system (NHMSS) constructed from
 parameters related to muscle strength and endurance (i.e.
odelling parts of the Fried operational deﬁnition of the frailty
yndrome), rotarod performance, grip strength and max  isometric
orce of the extensor digitorum longus muscle. Scores were con-
tructed by averaging the ratio of the parameter to its age group
easured mean, as well as to an age-predicted value obtained
y a multiple linear regression model using body and heart mass
s inputs. However, by deﬁnition, construction of this score was
nly possible for endpoint measurements. Accordingly, predictive
ower has not been evaluated.
Shortly afterwards, the same group (Liu et al., 2014) proposed a
clinically relevant frailty index for mice”. Four of the ﬁve Fried cri-
eria were emulated (weakness, slowness, physical inactivity and and Development 160 (2016) 34–40
exhaustion, but not weight loss) measuring grip strength, walking
speed on a rotarod and voluntary wheel running. Exhaustion was
emulated by an endurance measure using the averages from grip
strength and walking speed measures. Cut-offs were introduced at
1.5 SD below the age-associated mean and frailty was deﬁned as
at least 3 out of 4 criteria below cut-off. In this operationalization,
exhaustion is clearly a weak criterion due to its interdependence
with the grip strength and walking speed measures. To be consid-
ered frail, the animal has to match at least three of the deﬁned
criteria which are rated in a 5 point scale. With this approach the
prevalence of frailty found for cohorts of C56BL/6J mice is 9%, which
is consistent with the range of 7–16% calculated by Fried for humans
(Fried et al., 2001). Application of this scoring system allowed the
discrimination of older mice from unaffected adult animals using
a non-invasive approach. However, the validity of this index still
needs to be tested in longitudinal and intervention studies as well
as in other mouse strains.
2.2. Rockwood-based mouse frailty indices
Parks and colleagues (Parks et al., 2012), who proposed a frailty
index according to Rockwood type. In total, 31 parameters were
assessed describing physical activity, hemodynamic status, body
composition, basic metabolism and organ function. Some measure-
ments were invasive and thus unfavorably harmful for longitudinal
follow-up such as drawing high volumes of blood required for
metabolic measurements, or repeated exposure to x-rays. Never-
theless a frailty index could be compiled based upon a graded scale
measuring deviation from reference averages determined under
sex and age-matched conditions. Functional relevance of the index
is its distinct association with mouse age, with cardiac hypertro-
phy and peak contractile force. A frailty index constructed from
only 8 non-invasively measured parameters (describing physical
activity plus body weight) showed good correlations with the 31-
parameter index as well as with cardiomyocyte size. However, its
magnitude and variance increased as compared to the 31-item
index as expected. Moreover, this study (and especially the func-
tional association studies) was  done with very low numbers of
animals and, thus, was  most probably underpowered.
Later on, the same group went on to propose a different frailty
index based exclusively on parameters that can be easily assessed
by clinical observation, such as body temperature and weight mea-
surements (Whitehead et al., 2014). As studies in humans had
shown decreased discriminatory power of the frailty indices con-
structed from lower numbers of items, a total 31 parameters were
assessed. These items were generally derived from veterinarian
practice and used to monitor behavior and distress. Assessment
included evaluation of the integument, the musculoskeletal sys-
tem, auditory, ocular and nasal systems, digestive, urogenital and
respiratory systems, signs of discomfort, body weight and body
temperature. The severity of each deﬁcit was  rated using a sim-
ple scale of no deﬁcit, mild or severe grade. In comparison to the
8-item index developed before (Parks et al., 2012), the clinical 31-
item index showed improved reproducibility, better discrimination
between age groups and predicted mortality (albeit in one sin-
gle mouse only) and the major advantage of enabling longitudinal
assessment. The association of the clinical frailty index with (rela-
tive) age in the mouse was very similar to that found between the
70-parameter frailty index and age in humans, as observed in the
SHARE study (Börsch-Supan et al., 2013).3. Validation of frailty scales in mice
In lieu of a fully accepted frailty deﬁnition and the little knowl-
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ccepted assessment practice to diagnose and predict frailty is evi-
ent. The quantiﬁcation of frailty in experimental models of ageing,
hrough proper evaluation scales, is a key step to understand the
nderlying biology of frailty and ageing and to develop meaningful
reatments or preventive actions by targeting the involved mecha-
isms. In this chapter, we will review attempts to validate proposed
railty scales in mice in terms of response to interventions (includ-
ng genetic interventions) and inter-rater reliability. It should be
oted, that assessing the validity and reliability of tools to mea-
ure frailty is problematic even for humans where a much larger
atabase is available (Warnier et al., 2016).
Recently, Kane and colleagues (Kane et al., 2016a) analyzed the
ffects of genetic background (short-lived DBA/2J mice versus long-
ived C57Bl/6J) and of interventions with the potential to expand
ealthspan (40% caloric restriction and treatment with resvera-
rol) on the Rockwood-type frailty index as proposed by Whitehead
t al. (Whitehead et al., 2014). According to this study, both caloric
estriction and resveratrol signiﬁcantly reduced the frailty index
n male C57BL/6J, and there was a tendency for higher frailty
cores in the short-lived DBA/2J mice, which however was less than
xpected from the strain-speciﬁc differences in lifespan. This raises
he important question to what extent individual components of a
railty index may  need to be adjusted to take strain-speciﬁc dif-
erences into account. In the same study, caloric restriction had
o signiﬁcant effect on the frailty index in females (resveratrol
as only tested in males). Other studies have shown strong effects
f CR on lifespan in female C57Bl/6 but sex-speciﬁc effects on
ealthspan-related parameters (Cameron et al., 2012). It is possi-
le that the frailty index might be more sensitive to changes in
ealthspan than in lifespan, but this needs further work to be con-
rmed or refuted. Frailty-related parameters, but without a full
haracterization of frailty, were measured in a number of recent
ntervention studies in male C57Bl/6 mice aimed at expanding
ealthspan. For instance, Martin-Montalvo et al., 2013 assessed the
ffect of metformin on spontaneous activity, rotarod and threadmill
erformance and various metabolic parameters in male mice aged
6–22 months. Xu et al., 2015 measured effects of JAK inhibitor
reatment in mice aged around 26 months which were regarded
s frail (but not shown to be by any of the proposed scales). The
nhibitor improved spontaneous physical activity, grip strength and
otarod performance. Frailty has also been used to stratify cohorts
o analyze drug responses in old mice. Kane et al., 2016b found that
cetaminophen-induced hepatoxicity was not different between
rail and non-frail old mice, and there was also no change in hep-
toxicity with age overall. Still, stratiﬁcation by frailty is clearly an
mportant paradigm for intervention studies in old animals and is
xpected to become more commonly used in the near future.
.1. Frailty assessment in mutant mouse models of ageing
As for many diseases, genetically modiﬁed mice have proven
o be invaluable to identify key pathways and mechanistic drivers
n the ageing process. This is true for both models of accelerated
nd delayed ageing. In both cases (albeit with some higher urgency
n the case of accelerated ageing models) an essential question is
hether the genetic modiﬁcation targets a fundamental process
nderlying the whole ageing process in all or at least most of its
imensions or ‘only’ a speciﬁc disease or a ‘private’ ageing mech-
nism (Martin-Montalvo et al., 2013), i.e. one of relevance for a
ingle species or strain only. As recently outlined (Richardson et al.,
016), measuring ‘healthspan’ as an assessment of health over sev-
ral domains and a wide range of different ages will be necessary to
nswer the question whether a chosen intervention postpones the
geing process in its entirety or rather, at what costs certain impor-
ant aspects of ageing will be delayed. However, the much simpler
nd faster assessment of a treatment-induced shift in frailty should and Development 160 (2016) 34–40 37
sufﬁce to provide a ﬁrst answer to the question posed above, i.e.
whether the targeted process has the potential to inﬂuence ageing
in a fundamental way. Unfortunately, so far there is very little data
available on frailty measurements in genetically modiﬁed mouse
models of ageing.
A wide range of mice models with shortened lifespan and pre-
sumably accelerated ageing is available. This includes mice that
develop chronic inﬂammation (IL-10tm/tm and Nfb1−/−),mice with
accelerated senescence (SAMP), mitochondrial or DNA repair dys-
regulation (e.g. Polg−/−, Ercc1−/−, Bubr1 hypomorph), telomerase
shortening (Tert−/−) and others (Walston et al., 2008; Ko et al.,
2011; Sikka et al., 2013; Jurk et al., 2014; Takeda et al., 1981 10;
Derave et al., 2005; Trifunovic et al., 2004; Safdar et al., 2011; Dollé
et al., 2006; Baker et al., 2004, 2011; Choudhury et al., 2007).
The relevance of some of these models in ageing research has
been questioned, for instance because of their very short lifespan
(Ercc1−/−) or because they do not resemble any known human con-
dition (SAMP). A formal assessment of a frailty phenotype in these
models would thus be useful, but has so far only been performed
in mice deﬁcient for the anti-inﬂammatory cytokine interleukin
10 (IL-10tm/tm) according to a frailty scale developed by Walton
et al. ((Walston et al., 2008) see Table 2). IL-10tm/tm mice develop a
Crohn’s disease-like pathology in colon. However, when Il10 knock-
out mice are kept under speciﬁc pathogen-free (SPF) conditions,
they do not develop colon inﬂammation but yield a complex phe-
notype that includes several frailty features, such as sarcopenia,
muscular weakness, weight loss as well as age-related increase
of serum IL-6, interleukin 1 beta (IL-1), tumor necrosis factor
alpha (TNF-), interferon gamma  (IFN-) and growth-regulated
protein alpha (Gro-/KC), accompanied by blood vessel stiffness
and impaired cardiac function (Walston et al., 2008; Ko et al.,
2011; Sikka et al., 2013 Sikka et al., 2013). The simultaneous occur-
rence of all these features in a mouse renders it the ﬁrst mouse
model approximating human frailty syndrome and, therefore, an
excellent tool for the study of the interactions between low-grade
inﬂammation, the somatotropic axis of ageing and the development
of frailty. Another genetic model mimicking chronic inﬂamma-
tion is deﬁciency of NFB p105/p50 subunits in Nfb1−/− mice
resulting in a progeroid mouse model in which shorter lifespan
and progeria are driven by chronic progressive low grade inﬂam-
mation. In these mice, a relatively comprehensive assessment of
accelerated ageing phenotypes was  performed (Jurk et al., 2014)
using a range of laboratory parameters in combination with clini-
cal parameters similar to those proposed by Whitehead et al., 2014
for the assessment of frailty. Phenotypes in these mice include,
among others, sarcopenia, kyphosis, body weight loss and cardiac
hypertrophy. Since the Nfb1−/− mice fulﬁlled frailty criteria over
a wide range of physiological and biological domains Jurk et al.,
2014 concluded that progeria in Nfb1−/−mice is not just segmen-
tal, thus proving chronic inﬂammation as a cause of accelerated
ageing and frailty. This is in excellent accordance with human
studies, in which the chronic activation of inﬂammatory path-
ways is closely associated with frailty (Leng et al., 2007) even
at extreme old age (Arai et al., 2015) and has long been sus-
pected to play a causal role in its development (Franceschi, 2007).
Partial characterizations of frailty/accelerated ageing have been
performed in telomerase Tert−/− (Choudhury et al., 2007), DNA
excision repair cross-complementation group 1 ERCC1−/− (Dollé
et al., 2006; Niedernhofer et al., 2006), Polymerase gamma  (Polg)
(Trifunovic et al., 2004), BUB1 mitotic checkpoint serine/threonine
kinase B (BubR1) hypomorphs (Baker et al., 2004) or nucleotid
excision repair mice, to name just a few. Of speciﬁc interest for
a comprehensive assessment of frailty is the senescence- acceler-
ated mouse (SAM) model, which presents several substrains, with
a lifespan range between 9.7 and 13.3 months. These mouse lines
develop ageing features such as skin lesions, elevated amyloidosis,
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Table 2
Comparison of mouse frailty assessment tools.
Liu’s Frailty Indexa Whitehead’s Frailty Indexb Waltson’s Frailty Modelc
Based on Fried’s Frailty Phenotype Based on Rockwood’s Frailty Index Based on the characterization of IL10tmtm genetically
modiﬁed model
Assesses levels of physical performance and
strength/power
Assesses parameters of potential ageing related
deﬁcits
Models human frailty state of inﬂammation, weakness
at early age and cardiovascular dysfunction
No  Cognitive assessment Cognitive assessment Not reported Cognitive assessment
















































aa Ref. Liu et al., 2014.
b Ref. Whitehead et al., 2014.
c Ref. Walston et al., 2008.
yphosis, learning and memory deﬁcits, osteoporosis, muscle loss
tc. (Takeda et al., 1981 10; Derave et al., 2005). However, to our
nowledge, comparative assessments of frailty in different genetic
ntervention models have not been done yet. Similarly, there are
ew data on the effect of pharmacological or lifestyle-type interven-
ions on frailty in mutant ageing mice available, with the notable
xception of a study by Wang et al., 2014, testing a nutriceutical
rape seed extract in IL-10 knockout mice. Interestingly young mice
eceiving this extract in drinking water for 12 weeks had enhanced
uscle mass, reduced protein degradation and apoptosis, which
ranslated to amelioration of muscle wasting and thus frailty.
.2. Inter-rater reliability of mouse frailty indices
For frailty assessments to become a useful tool in mouse ageing
esearch, reliability and reproducibility of results between separate
ouse cohorts and separate laboratories need to be established.
his is especially important as frailty scales are mostly based on
ated, rather than measured, parameters. This question has only
ery recently been addressed, and to our knowledge only for the
ockwood-type index according to Whitehead et al., 2014. Kane
t al., 2016b showed that the frailty index developed by Whitehead
t al., 2014 gave comparable results to the original publication in
 different mouse cohort in a separate laboratory. Moreover, the
ame paper reported an excellent inter-rater correlation of 0.88
etween two raters. In a study by Feridooni et al., 2015 the inter-
ater correlation coefﬁcient between two raters was originally
ower (around 0.51). However, if individual rater experience was
sed to change the assessment protocols towards a more clearly
eﬁned operationalization, inter-rater correlations increased to
alues similar to those reported by Kane et al., 2016b. In two sub-
equent letters published previously (Kane et al., 2015; Howlett
nd Rockwood, 2015), these results were clariﬁed further. Kane
t al., 2015 showed that inter-rater reliability did not necessar-
ly improve just with increasing practice and experience of the
aters with the assessment, if it did not result in an adjustment
f the assessment protocols. However, raters with different profes-
ional background (animal technicians vs scientists) appeared to
ate differently, stressing the need for further standardization of
he operationalization procedures for the assessment of the frailty
ndex. It is also important to note that the results of Kane et al.,
016b and Feridooni et al., 2015 regarding inter-rater reliability
ere decidedly different for individual components of the frailty
ndex. Components that were frequently rated different in the Kane
t al., 2016b such as vision loss, body condition, grip strength, coat
ondition, mouse grimace scale, tail stiffening, eye discharge (all
ith ≤ 80% agreement) were not the same as those rated differ-
ntly in the Feridooni et al., 2015 which included hearing loss, body
emperature, menace reﬂex, tremor, hunched posture (with ≤ 80%
greement after optimization of protocol).4. Conclusions: potential for improvement
Frailty is a major phenotype of ageing, and there is an increasing
interest to identify and validate interventions than can postpone
and/or reverse frailty. Moreover, existing frailty scales and oper-
ationalizations are signiﬁcantly less laborious and expensive to
perform as a thorough assessment of healthspan (Richardson et al.,
2016). Thus, frailty may  be very useful as a simple ﬁrst indicator and
potentially as a screening tool for interventions aimed at improv-
ing healthspan in mice. In our opinion, the most important areas
for further development to support a wider use are the following:
i) Demonstrate frailty as a useful tool for assessing the efﬁciency
of healthspan-expanding interventions
The limited number of interventions tested so far for their
impact on frailty (Kane et al., 2016b; Graber et al., 2015) sug-
gest that frailty assessment is not used as often as it might
whereas it is a relatively simple and cheap intervention screen-
ing. However, more data will be necessary covering a wider range
of interventions. Moreover, data on whether and how well an
intervention-mediated change in frailty scores predicts additional
ageing phenotypes, especially healthspan and lifespan, will need
to be generated. We would like to propose to consider includ-
ing a frailty score into the phenotypes assessed as part of the
NIA Interventions Testing Program (www.nia.nih.gov/research/
dab/interventions-testing-program-itp).
ii) Test whether frailty scales are comparable between sexes and
amongst mutant strains
There are signiﬁcant differences in lifespan between males
and females from frequently used mouse strains, either under
basal conditions or following interventions. Not unfrequently, there
seem to be interactions between sex and housing conditions (test-
ing facility) in terms of lifespan. So far, it is not clear whether
these sex-related differences in lifespan are reﬂected in the frailty
scores of the mice. In genetically modiﬁed mice with either a
shortened or extended lifespan, formal frailty assessments have
almost never been performed (with the notable exception of the
IL-10tm/tm mice (Walston et al., 2008)), although some of the com-
ponents of Fried- and Rockwood-type frailty scales have been
employed as measures of healthspan in these mice. There is a
concern that some components of frailty scales (for instance hear-
ing loss or cataract) are expressed in a strongly strain-speciﬁc
fashion, which would complicate the assessment of a mutant
in comparison to wild-type littermates. However, strain-speciﬁc
normalization of the scales is a possibility to overcome this prob-
lem.
iii) Optimise the frailty concept, validate different frailty scales
against each other
Presently, at least three different concepts have been used to
measure frailty in mice (Walston et al., 2006; Whitehead et al.,
2014; Liu et al., 2014). It is not clear how well the concordance
between these concepts is. In humans, Fried and Rockwood frailty
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ngly, both scales showed largely consistent associations providing
 range of candidate biomarkers for ageing in a very old population
Collerton et al., 2012).
iv) Develop the operationalization protocols and clarify the
xtent of reproducibility
In terms of frailty scale operationalization and reproducibility,
he situation is different for the Fried- and Rockwood-type assays.
o our knowledge, no data are available yet about the reproducibil-
ty of the Fried-type frailty assessments (assay according to Liu
t al., 2014) in mice between observers and/or laboratories. It might
e assumed, that this assay is less sensitive to inter-observer vari-
tion, because fewer parameters are taken into account and these
re measured rather than rated. As discussed above, we believe
hat interdependency of the parameters used for operationaliza-
ion of frailty by Liu et al. is a weakness of the index. We suggest
hat inclusion of a measure of weight loss might improve the assay.
nintentional weight loss is a criterion in the human Fried frailty
cale and weight loss is a strong predictor of increased mortality
ate in humans (Miller and Wolfe, 2008). Mice (under ad libitum
eeding) also show a steady decline of body weight during their
nal weeks to months of life, and the age at which their body
eight reached its maximum was predictive of lifespan and asso-
iated with other healthspan measures in a study testing the role
f chronic inﬂammation in mice (Jurk et al., 2014).
By design, the Rockwood deﬁcit scale is open for the incorpora-
ion of additional parameters. A biomarker frailty index has already
een constructed for humans (Mitnitski et al., 2015). For mice, age-
ssociated changes in the vasculature, such as increased central
lastic large artery stiffness and endothelial dysfunction assessed
y pulse wave velocity could be informative, as could be mark-
rs of bone degeneration and osteoporosis or inﬂammation. There
ave been discussions whether and to which extent organ-speciﬁc
esion markers should be included into frailty scales of the Rock-
ood type. There are clearly multiple lesions that develop with
ge across a wide range of organs including lungs, kidneys, blad-
er, heart, spleen, adrenal glands, liver and others (Rowlatt et al.,
976; Turturro et al., 2002). However, if one accepts low cost and
ase of operation as major advantages of mouse frailty assess-
ents, it appears that the index according to Whitehead et al.
lready provides a good compromise between wide-ranging cov-
rage of ageing phenotypes and operational cost. As this index is
argely based on observation scores rather than objective measure-
ents, inter-rater reliability is an important issue. The few available
ata are very encouraging, as generally high correlation coefﬁcients
ere obtained when two independent ratings were compared. At
he same time, these results indicate the importance of developing
perating protocols as detailed and clearly as possible. Further-
ore, the dependency of ratings on professional background needs
urther interrogation and ways to operationalize the assessment
uch that background bias is minimized need to be found.
In conclusion, a broad consensus exists that frailty entails
ulti-organ dysfunction and increased vulnerability to additional
iseases, which suggests a link between mortality and frailty.
eans and measures for frailty assessment in combination with a
anel of valid biomarkers, which remain to be identiﬁed and stan-
ardized, will allow diagnosis and follow up of frailty conditions.
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